Because a number of shareholders had expressed concern that the apparent success of the Merck drug diminished the potential role of Lovaxin C.Princeton-based Advaxis (Nasdaq: ADXS) has issued ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in ...

When perusing the biotech sector, investors have more than 300 publicly traded companies on reputable exchanges that they can choose from. It's almost overwhelming, and it can make finding a company ...

Ayala Pharmaceuticals Inc., a clinical-stage oncology company headquartered in Delaware, and Princeton-based biotech firm Advaxis Inc. announced Oct. 19 that they entered into a definitive merger ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated (OTCBB: ADXS) and reversed a patent challenge made by Anza Therapeutics, ...

With $20 million on hand and the second part of a potentially registrational phase 2/3 study just getting underway, Ayala was facing a potential cash crunch. But Advaxis may have solved its ...

Title: A phase 1 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.Session Type: ...

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that Advaxis will be featured on Worldwide ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it ...

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that it will host its annual Investor & Analyst ...